Mar 20 |
SNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…
|
Mar 15 |
Soligenix GAAP EPS of -$0.79
|
Mar 15 |
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
|
Feb 8 |
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
|
Jan 26 |
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
Jan 25 |
Soligenix to Present at The Microcap Conference
|
Jan 16 |
Soligenix files to sell 10.64M shares of common stock, warrants
|
Jan 10 |
SNGX: Phase 2a Psoriasis Trial Achieves Clinical Success…
|
Jan 8 |
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
|
Jan 4 |
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
|